Skip to main content

Table 4 Contribution of LAP to the risk of all-cause mortality, independent of common CVD risk factors among men and women.

From: Predictive performances of lipid accumulation product vs. adiposity measures for cardiovascular diseases and all-cause mortality, 8.6-year follow-up: Tehran lipid and glucose study

 

Men

Women

 

HR* (95% CIs)

P-value

HR* (95% CIs)

P-value

Age (years)

1.09 (1.07-1.11)

<0.001

1.14 (1.11-1.18)

<0.001

Smoking

2.01 (1.32-3.04)

0.001

2.27 (0.69-7.50)

0.179

Premature history of CVD

0.58 (0.23-1.41)

0.228

1.16 (0.55-2.47)

0.692

Diabetes

1.52 (0.86-2.69)

0.151

1.30 (0.51-3.34)

0.579

Antihypertensive drug use

1.97 (1.31-2.98)

0.001

1.59 (0.92-2.74)

0.094

Systolic blood pressure (mmHg)

1.20 (1.03-1.40)

0.022

1.03 (0.80-1.32)

0.822

Intervention

0.69 (0.47-1.02)

0.061

1.10 (0.66-1.84)

0.708

Non-HDL-C (mmol.l-1)

0.94 (0.75-1.18)

0.595

0.86 (0.64-1.15)

0.295

HDL-C (mmol.l-1)

0.87 (0.69-1.08)

0.197

0.93 (0.71-1.22)

0.582

FPG (mmol.l-1)

1.19 (0.82-1.72)

0.366

0.67 (0.34-1.32)

0.253

2h-PCPG (mmol.l-1)

1.02 (0.79-1.31)

0.892

1.18 (0.86-1.63)

0.310

Ln LAP (cm.mmol.l-1)

0.74 (0.61-0.90)

0.003

0.88 (0.60-1.30)

0.530

  1. * For one SD increment in each continuous predictor, obtained from multivariate Cox proportional hazards regression model adjusted for age, smoking, systolic blood pressure, family history of premature CVD, diabetes, antihypertensive drug usage, HDL and non-HDL cholesterol, FPG, and 2h-PCPG , plus the TLGS intervention measures.
  2. CVD, cardiovascular disease; FPG, fasting plasma glucose; HDL-C, high density lipoprotein cholesterol; HR, hazard ratio; LAP, lipid accumulation product; Ln, naturally logarithmically transformed; 2h-PCPG, 2-hour post-challenge plasma glucose;